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Gene Therapy for blood genetic diseases 
 • Rare genetic disorder characterized by loss of T, B and NK immune 
cells and metabolic defects, caused by lack of ADA 
• Lethal in the first years of life, unless patients are kept in complete 
isolation; ERT available 
• Fully matched allogeneic bone marrow transplantation available to 
less than 1/3 of patients 
ADA- Severe combined immunodeficiency 
Gene therapy for ADA-  SCID 
A. Aiuti et al., N. Engl. J. Med., 2009 
• 14 patients treated from 2000 to 2009 
• 100% survival, 4 to 14 yrs follow-up. No side effects 
• Engraftement of gene-corrected stem cells at 1% to >10% levels, 
selective advantage for gene-corrected T- cells 
• Immunological reconstitution in all patients, and correction of the 
systemic metabolic defect in the majority of patients 
• Protection from infections and normalization of growth parameters 
(height and weight) with no need for enzyme replacement therapy 
(12/14 patients) 
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months after gene therapy   






Hacein-Bey-Abina et al Science 2003; Hacein-Bey-Abina et al JCI 2008; Howe et al JCI 2008; 
Hacein-Bey-Abina et al NEJM 2010; Gaspar et al Sci Transl Med 2011;  
+ unpublished data courtesy of Salima Hacein-Bey and Adrian Thrasher 
Gene therapy for SCID-X1 (IL2RG deficiency) 






Mapping viral integration sites in the genome 
~3 doublings 
virus - host genome  
junctions  
Library of virus - host genome junction amplicons   Analysis 
>90% CD34+  
>40% CD133+ 
Illumina sequencing 
The epigenetic landscape of mammalian chromatin  
MLV integrates in regulatory regions 
A. Cavazza et al., Stem Cell Reports, 2016 
MLV integrates in regulatory regions: the LMO2 locus 
Frequency of integration in the LMO2 locus: 1:1,200 
LTR LTR 
MLV interferes with normal gene function 
Therapeutic gene 
LTR LTR Therapeutic gene 
Retroviral vector 
Retroviral vector 
Gene A Gene B 
Gene C 
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Cavazza et al., Hum. Gene Ther. 2013 
BET proteins 
(histone acetylases) 
HIV targets genes at the nuclear periphery 
Marini et al., Nature 2015 
• X-linked, rare primary immunodeficiency 
• Multiple symptoms: 
 - Hemorrhage (microthrombocytopenia) 
 - Immunodeficiency 
 - Eczema 
 - Auto-immune disorders   
 - Lymphoreticular malignancies 
• Lack of WASP, a cytoskeletal component 
• Treated by transplantation of allogeneic HSC 
Gene Therapy for Wiskott-Aldrich Syndrome  
• pCCL-Wp-WAS  is a replication-defective, self-inactivating lentiviral 
vector derived from HIV1 and pseudotyped with VSV-G    
 
• The vector contains the human WAS cDNA driven by its endogenous 
1.6-kb promoter. 
 
Gene Therapy for Wiskott-Aldrich Syndrome  
• 13 patients 0.8 to 15.5 years of age treated in three centers in 
Europe and the US 
• 12/13 patients alive with follow-up of 4-50 months 
• rapid and sustained immune reconstitution, substantial clinical 
improvement (cleared eczema), sustained though slower, and 
in some patients incomplete, platelet reconstitution 
• no treatment-related severe adverse events 
• polyclonal vector integration pattern, no evidence for skewed 
hematopoietic reconstitution or clonal dominance 
Gene Therapy for WAS: results  
The WAS gene therapy trials 
Gene therapy for WAS: insertion site analysis 
Hacein-Bey Abina et al., JAMA 2015 
Aiuti A. et al., Science 2014 
     Active clinical trials 
• SCID-X1 (BCH, UCL, Necker) 
• Adrenoleukodystrophy (Bluebird Bio) 
• Metachromatic Leucodystrophy (TIGET) 
• Chronic Granulomatous Disease (Genethon, UCLA, BCH, NIH) 
• Fanconi Anemia (CIEMAT, FHCC) 
• β-thalassmia/HbE (Bluebird Bio) 
• β-thalassemia (TIGET) 
• Sickle-Cell Disease (Bluebird Bio) 
• Sickle-Cell Disease (UCLA) 
Gene Therapy for blood genetic diseases 
Sickle cell disease 
From: Hardison & Blobel, Science 342:206, 2013 
HbF ameliorates the symptoms of sickle-cell disease 
chr11 
Adult BCL11A binding site 
Adult GATA1 binding site 
Thalassemias 
HPFH 
HPFH is caused by gene deletion 
13.6 kb region 
Fetal GATA1 binding site 
Adult genes Fetal genes 
Editing via 
homologous recombination 














Targeted genome editing 
ZFN CRISPR-Cas9 
Targeted deletion in HUDEP2 cells 
HUDEP2 cells 

























Targeted deletion in HUDEP2 cells (13.6 kb) 
HUDEP2 cells 




         Junction position 		I	
AACCCAAGAGTCTTCTCTGTCTCCACATCTAAGGGTCTTGGGTACAGGAGTTTGA  Del  
AACCCAAGAGTCTTCTCTGTCTCCACATCTAAGGGTCTTGGGTACAGGAGTTTGA  50.0% (7/14) 
AACCCAAGAGTCTTCTCTGTCTCCACAT--AAGGGTCTTGGGTACAGGAGTTTGA  35.7% (5/14) 
AACCCAAGAGTCTTCTCTGTCTCCACATGCTAAGGGTCTTGGGTACAGGAGTTTA   7.1% (1/14) 
AACCCAAGAGTCTTCTCTGTCTCCACATCG-AGGGTCTTGGGTACAGGAGTTTGA   7.1% (1/14) 
 
 
         Junction position 		I 
AACCCAAGAGTCTTCTCTGTCTCCACATGAAGTATGTAGCACCCTCAAACCTAAA  5’ I nv  
AACCCAAGAGTCTTCTCTGTCTCCACATGAAGTATGTAGCACCCTCAAACCTAAA  56.2% (9/16) 
AACCCAAGAGTCTTCTCTGTCTCCACATG--GTATGTAGCACCCTCAAACCTAAA  25.0% (4/16) 
AACCCAAGAGTCTTCTCTGTCTCCACATGGAAGTATGTAGCACCCTCAAACCTAA  18.8% (3/16) 
	
  
         Junction position 		I 
GGTTTAAGGAGACCAATAGAAACTGGGCCTAAGGGTCTTGGGTACAGGAGTTTGA  3’ I nv 
GGTTTAAGGAGACCAATAGAAACTGGGCCTAAGGGTCTTGGGTACAGGAGTTTGA  42.9% (6/14) 
GGTTTAAGGAGACCAATAGAAACTGGGC-TAAGGGTCTTGGGTACAGGAGTTTGA  35.7% (5/14) 
GGTTTAAGGAGACCAATAGAAACTGGG------GGTCTTGGGTACAGGAGTTTGA  14.3% (2/14) 
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 • Gene knock-out and genomic deletions are relatively efficient in hematopoietic stem 
cells. In a few indications, these could be effective forms of therapy (e.g., CCR5 KO in 
AIDS gene therapy) 
• Gene correction by HR-mediated DNA repair requires a different therapeutic for each 
mutation in any given gene, a complex and very expensive approach; in addition, HR 
has an exceedingly low efficiency in somatic stem cells, far from what would be 
required for medical application, with few exceptions (e.g., a strong selective 
advantage for corrected cells) 
• Gene deletions are not an obvious target for the existing gene editing technology 
• The consequences of introducing double-stranded DNA breaks in somatic stem cells 
are far from being understood: gene editing is not necessarily safer than viral-
mediated gene addition 
Genome editing vs. gene replacement therapy 
  
A Galy, S. Charrier, A Viornery, 
K. Seye, G. Cedrone,  
 
HIV-vector  development 
O.Merten   F. Barnay-Toutain, E. 
Galene  
 
Regulatory-Clinical Affairs, QA  
G. Honnet, D. Caizergues, M. 
Keen, M. Souquieres , H. Haddad, 
A. Kobrine 
  
GENOSAFE, Evry, France 
M. Audit, A. Botrel, M. Dessainte 
 
MHH, Hannover, Germany 
C. Baum, U. Modlich, S. Knoss 
 
TIGET, Milan , Italy 
L. Naldini, MG Roncarolo, A. Aiuti 
 
INSTITUTE OF CHILD HEALTH – 
GREAT ORMOND STREET HOSPITAL,  London  
A. Thrasher, B. Gaspar 
C. Rivat, E. De Falco, K. Buckland, K. Parsley 
A.M. McNichol, S. Swift, M. Blundell, G. Bouma 
N. Himmoudi  
 
NECKER HOSPITAL, Paris 
M. Cavazzana, S. Hacein-Bey Abina,  
A. Fischer, S. Blanche, J. Blondeau,  
L. Caccavelli  
  
CHILDREN’S HOSPITAL, Boston, MA 
D. Williams, SY. Pai, L. Notarangelo 
M. Armant, G. Kao, M. Wladkovski, O. Sturtevant 
 
UNIVERSITY OF PENNSYLVANIA, Philadelphia 
F. Bushman, N. Malani, C. Berry 
 
GEORG SPEYER HAUS, Frankfurt, Germany 
M. Grez 
Gene Therapy for WAS: the teams 
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